Diabetic retinopathy risks studied

Article

Severity linked to progression; younger age, macular oedema may also be involved

Interesting new findings have emerged from a study of the risk factors for the development and progression of diabetic retinopathy, namely, that its severity determines the rate of progression, especially in younger patients.

"Diabetic retinopathy is the major cause of visual impairment and blindness worldwide," said Dr Tan, consultant, Department of Ophthalmology, Tan Tock Seng Hospital, National Healthcare Group Eye Institute, Singapore.

"One reason for this may be the interrelationships among the various risk factors," he explained.

In light of these discrepancies, Dr Tan and colleagues studied patients with the disease over the course of 5 years as well as the risk factors associated with different facets of the disease: pre-existing diabetic retinopathy, the development and rate of progression of diabetic retinopathy, and development of clinically relevant diabetic macular oedema.

A total of 250 patients (mean age, 66 years) (500 eyes) with type 2 diabetes were included and followed for more than 5 years. Patients with coexisting ocular pathologies or a history of ocular surgeries were excluded. The diabetic retinopathy was graded using the Early Treatment of Diabetic Retinopathy Study classification. The results underwent univariate and multivariate analyses.

Related Videos
ARVO 2024: Andrew D. Pucker, OD, PhD on measuring meibomian gland morphology with increased accuracy
 Allen Ho, MD, presented a paper on the 12 month results of a mutation agnostic optogenetic programme for patients with severe vision loss from retinitis pigmentosa
Noel Brennan, MScOptom, PhD, a clinical research fellow at Johnson and Johnson
ARVO 2024: President-elect SriniVas Sadda, MD, speaks with David Hutton of Ophthalmology Times
Elias Kahan, MD, a clinical research fellow and incoming PGY1 resident at NYU
Neda Gioia, OD, sat down to discuss a poster from this year's ARVO meeting held in Seattle, Washington
Eric Donnenfeld, MD, a corneal, cataract and refractive surgeon at Ophthalmic Consultants of Connecticut, discusses his ARVO presentation with Ophthalmology Times
John D Sheppard, MD, MSc, FACs, speaks with David Hutton of Ophthalmology Times
Paul Kayne, PhD, on assessing melanocortin receptors in the ocular space
Osamah Saeedi, MD, MS, at ARVO 2024
© 2024 MJH Life Sciences

All rights reserved.